The role of clopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation.
@article{Kayacioglu2008TheRO,
title={The role of clopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation.},
author={Ilyas Kayacioglu and Rafet Gunay and H{\"u}seyin Şaşkın and Mustafa Idiz and Yavuz Sensoz and Mehmet Şanser Ateş and Burak Tangurek and Ahmet Taha Alper and Mahmut Murat Demirtaş and Ibrahim Yekeler},
journal={The heart surgery forum},
year={2008},
volume={11 3},
pages={
E152-7
}
}BACKGROUND
Reactive thrombocytosis has been reported in 20% of patients after coronary artery bypass grafting (CABG), a frequency that might be related to the high incidence of thrombotic complications. The present study was planned to investigate the effect of combined treatment with clopidogrel and acetylsalicylic acid (ASA) on post-CABG reactive thrombocytosis.
METHODS
Included in this prospective, randomized study were 60 patients who underwent CABG operation with a 6-month follow-up…
29 Citations
Efficacy and Safety of Dual Antiplatelet Therapy on Graft Patency After Coronary Artery Bypass Graft Surgery: A Randomized Controlled Trial
- Medicine
- 2020
This study did not demonstrate the superiority of the DAPT regimen over aspirin monotherapy in patients undergoing elective CABG, and larger multicenter studies may provide more evidence.
Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials
- MedicineBMC Surgery
- 2015
Limited RCT data with heterogeneous trial designs suggest that higher intensity (prasugrel or ticagrelor) but not lower intensity (clopidogrel) DAPT is associated with an approximate 50 % lower mortality in ACS patients who underwent CABG based on post-randomization subsets from single RCTs.
Early dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass surgery: survival and safety outcomes.
- MedicineThe Journal of cardiovascular surgery
- 2020
Compared with ASA, DAPT showed a non-significant impact on long- term survival and demonstrated to be a safe option and further studies are needed to provide recommendations on the therapeutical strategy following CABG.
Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention: clinical and cost-effectiveness analyses.
- Medicine, Political ScienceCADTH technology overviews
- 2012
The aim of this report is to compare clopidogrel with other antiplatelet agents for the secondary prevention of vascular events in adults undergoing percutaneous coronary intervention (PCI).
Antiplatelet therapy and coronary artery bypass grafting: a systematic review and network meta-analysis.
- MedicineInteractive cardiovascular and thoracic surgery
- 2020
It is suggested that DAPT improves saphenous vein graft patency, mortality and major adverse cardiovascular event and should be considered for acute coronary syndrome patients after their CABG, at the expense of an increased risk for major bleeding.
High mean platelet volume to platelet count ratio as a predictor on poor outcomes after CABG
- MedicineGeneral Thoracic and Cardiovascular Surgery
- 2019
A high MPV/PC ratio is associated with early vein-graft occlusion and poor postoperative outcomes in the early period after CABG, and it has a negative effect on late survival.
Extreme Thrombocytosis in Trauma Patients: Are Antiplatelet Agents the Answer?
- MedicineThe American surgeon
- 2009
After adjusting for maximum platelet counts and duration of ExT, there was no difference between the treated and untreated groups in terms of mortality, complications, and intensive care unit or hospital lengths of stay.
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events.
- MedicineThe Cochrane database of systematic reviews
- 2017
The benefit and harm of adding clopidogrel to aspirin therapy for preventing cardiovascular events in people who have coronary disease, ischaemic cerebrovascular disease, peripheral arterial disease, or were at high risk of atherothrombotic disease, but did not have a coronary stent are reviewed.
Mean platelet volume/platelet count ratio as a predictor of long-term mortality after non-ST-elevation myocardial infarction
- MedicinePlatelets
- 2011
It is suggested that using the MPV/platelet ratio will magnify any existing relationship between platelet indices and mortality post-NSTMI and further studies are needed to confirm this finding.
References
SHOWING 1-10 OF 23 REFERENCES
IMPROVED AORTOCORONARY BYPASS PATENCY BY LOW-DOSE ASPIRIN (100 mg DAILY) Effects on Platelet Aggregation and Thromboxane Formation
- MedicineThe Lancet
- 1984
Reactive thrombocytosis following coronary artery bypass surgery: a possible link to a lipid dysfunction.
- MedicineThe Journal of cardiovascular surgery
- 1996
It was found that the preoperative S-Cholesterol level was significantly higher in the RT group, while hemostasis and anti-inflammatory parameters did not differ RT vs non-RT, suggesting that RT is linked to a lipid dysfunction and further studies are on-going.
A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency.
- MedicineThe New England journal of medicine
- 1982
In this trial dipyridamole and aspirin were effective in preventing graft occlusion early after operation and this benefit in graft patency persisted in each of over 50 subgroups.
Reactive thrombocytosis after coronary bypass surgery. An important risk factor.
- MedicineEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
- 1995
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
- Medicine, BiologyThe New England journal of medicine
- 2001
The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation, however, the risk of major bleeding is increased among patients treated with clopIDogrel.
EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION
- Medicine, Biology
- 2001
The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation, however, the risk of major bleeding is increased among patients treated with clopIDogrel.
Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study.
- MedicineCirculation
- 1988
Early vein graft patency was improved after CABG with all aspirin-containing drug regimens and was greater in all the treatment groups that received aspirin compared with the two nonaspirin groups.
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
- Medicine, BiologyThe Lancet
- 1996
A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
- Medicine, Biology
- 1996
Long-term administration of clopidogrel to patients with atherosclerotic vascular disease is more effective than aspirin in reducing the combined risk of ischaemic stroke, myocardial infarction, or vascular death.
Ticlopidine and clopidogrel.
- Biology, MedicineCirculation
- 1999
Important outstanding issues are whether clopidogrel adds to the benefit of aspirin and whether the combination of these agents is safe and whether this combination may become the standard for antithrombotic therapy in cardiovascular disease.





